Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevantolol - SOM Biotech

Drug Profile

Bevantolol - SOM Biotech

Alternative Names: Bevantolol-hydrochloride; CI-775; NC-1400; SOM-3355

Latest Information Update: 05 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Chemiphar
  • Developer SOM Biotech
  • Class Antidementias; Antihypertensives; Ischaemic heart disorder therapies; Neuroprotectants; Phenethylamines; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Huntington's disease

Most Recent Events

  • 28 Mar 2022 SOM Biotech initiates a phase II trial in Huntington's disease (In adults, In the elderly) in Spain (PO) (EudraCT2021-003453-28) (NCT05475483)
  • 15 Dec 2021 SOM Biotech plans a phase IIb trial for Huntington’s disease in the first quarter of 2022
  • 15 Dec 2021 MegaPharm enters into distribution and marketing agreement with SOM Biotech for Bevantolol in Israel
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top